Aspirin for treating depression, a randomized double blind controlled clinical trial

Aspirin as an augmenting to citlaopram for treating major depressive disorder, a randomized double blind placebo controlled clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201306203930N27

Enrollment

Registered

2013-07-16

Start date

2013-06-17

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive disorder. Depressive episode

Interventions

Intervention 1: Citalopram 20mg/day+Aspirin (160mg/day) for 6 weeks. Intervention 2: Citalopram 20mg/day+Placebo for 6 weeks.

Treatment - Drugs

Placebo

Citalopram 20mg/day+Aspirin (160mg/day) for 6 weeks

Citalopram 20mg/day+Placebo for 6 weeks

Eligibility

Sex/Gender

All

Age

17 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with major depressive disorder according to DSM-VI, both gender, and aged between 17 and 70 years old. Exclusion criteria: receive NSAIDs concurrently, reported positive history of cancer, serious medical condition, and hypothyroidism.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hamilton Derepssion Rating Scale. Timepoint: baseline, 2 week, and 6 week. Method of measurement: Interveiwe.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Ghanizadeh

Shiraz University of Medical sciences

ghanizad@sina.tums.ac.ir+98 71 1235 7282

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026